A Single-arm Exploratory Study of Safety and Efficacy of Tislelizumab in Combination With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Cancer
Latest Information Update: 25 Oct 2024
Price :
$35 *
At a glance
- Drugs Oxaliplatin (Primary) ; Tegafur (Primary) ; Tislelizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms WuhanUHGI001
- 17 Aug 2024 Results of 2-year outcomes and biomarker analysis published in the Annals of Surgical Oncology
- 22 Jan 2022 Interim results presented at the 2022 Gastrointestinal Cancers Symposium
- 20 May 2021 New trial record